NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

PFS was the primary endpoint of the DCVax-L trial. naive OS was the secondary endpoint. From the original protocol posted on clinicaltrials.gov:

Primary Outcome Measures:
1. The primary objective of this study is to compare progression free survival from time of randomization between patients treated with DCVax-L and control patients.
[ Time Frame: Time to tumor progression or death ]

Secondary Outcome Measures:
1. The secondary objective is to compare overall survival and time to disease progression between DCVax-L treated and control patients.
[ Time Frame: Until Death ]

Bottomline, PFS and OS are both "REAL" data results.